Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.52 |
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.40 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14687523 | 1.00 | CA2 (0.52) | CA2CA1DPP7SLC15A1TLR8 | |
| SCHEMBL14819788 | 0.94 | CA1 (0.45) | CA2CA1DPP7SLC1A2SLC1A1 | |
| SCHEMBL16327658 | 0.92 | GPR84 (0.44) | CA2CA1EPHX1 | |
| SCHEMBL22577460 | 0.92 | GPR84 (0.44) | CA2CA1EPHX1 | |
| SCHEMBL31520092 | 0.92 | GPR84 (0.44) | CA2CA1EPHX1 | |
| SCHEMBL3867719 | 0.86 | — | — | |
| SCHEMBL2420397 | 0.86 | — | — | |
| SCHEMBL14345861 | 0.84 | CA2 (0.43) | CA2CA1DPP7SLC15A1MAPK1 | |
| SCHEMBL10016030 | 0.84 | CA2 (0.43) | CA2CA1DPP7SLC15A1MAPK1 | |
| Hydrochloric Acid SCHEMBL28241321 | 0.84 | CA1 (0.39) | CA2CA1DPP7SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160244484-A1 | ANTI-INFLAMMATORY TRIPEPTIDES | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2016-08-25 | — | — | US | claimed |
| WO-2011149995-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA [C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | claimed |
| US-12030888-B2 | Himastatin derivatives, and processes of preparation thereof, and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230365628-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365627-A1 | MACROCYCLIC PEPTIDE BORONATE IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230183292-A1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-15 | — | — | US | disclosed |
| EP-4092038-A1 | OPIOID AGONIST PEPTIDES AND USES THEREOF | Protagonist Therapeutics, Inc. (US) | 2022-11-23 | — | — | EP | disclosed |
| US-20220289750-A1 | HIMASTATIN DERIVATIVES, AND PROCESSES OF PREPARATION THEREOF, AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2022-09-15 | — | — | US | disclosed |
| US-10954269-B2 | Anti-inflammatory tripeptides | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2021-03-23 | — | — | US | disclosed |
| US-20190153029-A1 | ANTI-INFLAMMATORY TRIPEPTIDES | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2019-05-23 | — | — | US | disclosed |
| US-20160244484-A1 | ANTI-INFLAMMATORY TRIPEPTIDES | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2016-08-25 | — | — | US | disclosed |
| US-20030229024-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | AUDIA JAMES E (US) | 2003-12-11 | — | — | US | disclosed |
| US-6476263-B1 | Compounds for inhibiting β-amyloid peptide release and/or its synthesis | ELAN PHARMACEUTICALS, INC. | 2002-11-05 | — | — | US | disclosed |
| US-20020052322-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | ELAN PHARMACEUTICALS, INC. | 2002-05-02 | — | — | US | disclosed |
| US-6211235-B1 | ALZHEIMERS DISEASE | ELAN PHARMACEUTICALS, INC. | 2001-04-03 | — | — | US | disclosed |
| US-6207710-B1 | FOR THERAPY OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. | 2001-03-27 | — | — | US | disclosed |
| US-6191166-B1 | ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. | 2001-02-20 | — | — | US | disclosed |
| EP-0942924-A2 | METHODS AND COMPOUNDS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | Elan Pharmaceuticals, Inc. (US) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998022494-A9 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | — | 1998-08-20 | — | — | WO | disclosed |
| WO-1998022494-A2 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030888-B2 | Himastatin derivatives, and processes of preparation thereof, and uses thereof | PCSK9, HMGCR, PCSK7 | CA2 2553/4885CA1 3610/4885DPP7 321/4885 |
| US-20020052322-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | APP, BACE1, IAPP | CA2 1983/4885CA1 208/4885DPP7 110/4885 |
| US-20160244484-A1 | ANTI-INFLAMMATORY TRIPEPTIDES | VIP, TNF, ENPEP | CA2 1882/4885CA1 1289/4885DPP7 27/4885 |
| US-20230365627-A1 | MACROCYCLIC PEPTIDE BORONATE IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | CA2 4500/4885CA1 4069/4885DPP7 1173/4885 |
| US-20190153029-A1 | ANTI-INFLAMMATORY TRIPEPTIDES | VIP, TNF, ENPEP | CA2 1882/4885CA1 1289/4885DPP7 27/4885 |
| US-20030229024-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | APP, BACE1, IAPP | CA2 1983/4885CA1 208/4885DPP7 110/4885 |
| US-10954269-B2 | Anti-inflammatory tripeptides | VIP, TNF, ENPEP | CA2 1882/4885CA1 1289/4885DPP7 27/4885 |
| US-20230183292-A1 | IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | CA2 4879/4885CA1 4876/4885DPP7 1354/4885 |
| US-20230365628-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | CA2 4879/4885CA1 4798/4885DPP7 869/4885 |
| US-20220289750-A1 | HIMASTATIN DERIVATIVES, AND PROCESSES OF PREPARATION THEREOF, AND USES THEREOF | PCSK9, HMGCR, PCSK7 | CA2 2553/4885CA1 3610/4885DPP7 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.